University of Toronto

IABC/Toronto #OVATION24 Award Winners Announced

Retrieved on: 
Monday, April 8, 2024

The #FindYourPossible Career Advancement Expo precedes the OVATION Awards Celebration, offering a unique blend of networking and professional growth, catering to communicators at all career stages.

Key Points: 
  • The #FindYourPossible Career Advancement Expo precedes the OVATION Awards Celebration, offering a unique blend of networking and professional growth, catering to communicators at all career stages.
  • This event shines a light on the spectacular work of award winners, which has been evaluated by a group of judges against the Global Standard of the Communications Profession .
  • Using the IABC Seven-Point Scale of Excellence, this year's award winners demonstrated outstanding work in communications, marketing, and PR within the Greater Toronto Area (GTA) across various disciplines, including corporate communications, public relations, media relations, advertising, and more.
  • To learn more about the #FindYourPossible Career Advancement Expo and #OVATION24 dates, times, and to purchase tickets, please visit: https://toronto.iabc.to/2024-ovation- awards /

Impressive $3.3M investment in Basic Mental Health Research

Retrieved on: 
Tuesday, March 19, 2024

Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.

Key Points: 
  • Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.
  • The Basics of Better Mental Health Program funds basic research that will provide insight into the causes and onset of mental health conditions, explore the neuropathological changes and information-processing deficits that may eventually lead to new directions for treatments and interventions, and explore the role of sex and gender in mental health.
  • "Brain research plays a critical role in increasing our understanding of the causes and onset of mental health conditions,” says the Honourable Ya’ara Saks, Minister of Mental Health and Addictions.
  • “I am thrilled to support the work being done through the Basics of Better Mental Health Program – this work will support better mental health for all Canadians.”
    “The inclusion of sex-specific biological considerations is instrumental in understanding the biological roots of mental health conditions,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

Retrieved on: 
Tuesday, April 2, 2024

Using neuromodulation technology, HeadaTerm 2 releases targeted electrical impulses to increase pain tolerance of its users.

Key Points: 
  • Using neuromodulation technology, HeadaTerm 2 releases targeted electrical impulses to increase pain tolerance of its users.
  • HeadaTerm 2 is a testament of WAT Medical's continued commitment to providing safe, effective, and user-friendly innovative medical devices at the most competitive price.
  • It provided an affordable solution to a debilitating condition that affects nearly 40 million people in the U.S. HeadaTerm 2 is a rechargeable device that features adjustable intensity setting and will be the most affordable device of its kind.
  • HeadaTerm 2 will appear at the 66th Annual Scientific Meeting in June 2024 hosted by American Headache Society.

The Future of Accessibility: Toyota Mobility Foundation and MaRS Discovery District Launch the Mobility Unlimited Hub in Toronto

Retrieved on: 
Friday, March 8, 2024

In a significant step towards creating a more inclusive society, Toyota Mobility Foundation (TMF) and MaRS Discovery District are proud to announce the launch of the Mobility Unlimited Hub.

Key Points: 
  • In a significant step towards creating a more inclusive society, Toyota Mobility Foundation (TMF) and MaRS Discovery District are proud to announce the launch of the Mobility Unlimited Hub.
  • The Mobility Unlimited Hub will work to foster innovation by offering a path to successful commercialization.
  • While establishing the Mobility Unlimited Hub, Toyota Mobility Foundation and MaRS worked closely with Toronto Global, a team of experienced business advisors assisting global organizations to expand into the Toronto Region.
  • The launch of the Mobility Unlimited Hub in Toronto is just the beginning.

OBSI announces new board members

Retrieved on: 
Friday, March 1, 2024

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:

Key Points: 
  • TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:
    Mary Condon has joined the board as a Consumer Interest Director.
  • Previously, she was a board member of the Capital Markets Authority Implementation Organization, and Commissioner and board member of the Ontario Securities Commission (OSC), where she was also a Vice-Chair.
  • All directors have a fiduciary duty to OBSI and do not advocate for or represent any outside interest while engaged in OBSI governance.
  • If a consumer has a complaint against an OBSI participating bank or investment firm that they are not able to resolve with the bank or firm, OBSI will investigate at no cost to the consumer.

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Tuesday, February 27, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.
  • The following presentations occurred at AAAAI 2024:
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users
    Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use
    Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation)
    The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety
    Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation)
    Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks
    Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation)
    The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation)
    Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation)
    Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times
    Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation)
    “The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments.
  • The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.”

CMHC Announces Housing Research Award Winners

Retrieved on: 
Thursday, February 29, 2024

The Housing Research Awards recognize Canadian housing research, research training, knowledge mobilization and outreach activities that are impactful and innovative and help to build and sustain Canada's culture of research-based housing knowledge across key fields, including the social sciences and humanities, health, and technology.

Key Points: 
  • The Housing Research Awards recognize Canadian housing research, research training, knowledge mobilization and outreach activities that are impactful and innovative and help to build and sustain Canada's culture of research-based housing knowledge across key fields, including the social sciences and humanities, health, and technology.
  • Thank you to all of those who submitted their work for the 2023 Housing Research Awards, and congratulations to our winners.
  • This is the highest Housing Research Awards honour, recognizing a significant research contribution that helps us achieve our aspiration to make housing affordable for everyone in Canada.
  • CMHC contributes to the stability of the housing market and financial system, provides support for Canadians in housing need, and offers objective housing research and information to all levels of governments, consumers and the housing industry.

Rapid Silicon Leads the Way with First Complete Open-Source FPGA EDA Tool-Chain

Retrieved on: 
Tuesday, February 20, 2024

This marks a significant shift for Rapid Silicon, as it transitions from a hybrid model to a full open-source model, embracing a 100% open-source flow.

Key Points: 
  • This marks a significant shift for Rapid Silicon, as it transitions from a hybrid model to a full open-source model, embracing a 100% open-source flow.
  • The launch of Raptor Design Suite signifies a game-changing moment for the EDA industry, offering unparalleled accessibility and flexibility to designers worldwide.
  • With a comprehensive array of features, Raptor Design Suite empowers users with a complete end-to-end open-source tool flow.
  • "We are pleased to announce the Raptor Design Suite, the industry's first end-to-end 100% open-source FPGA SDK and Compiler," said Alain Dargelas, VP of Software at Rapid Silicon.

University of Waterloo - School of Accounting and Finance Wins The 2024 CFA Society Toronto Ethics Challenge

Retrieved on: 
Monday, February 12, 2024

On February 08, 2024, University of Waterloo - School of Accounting and Finance was awarded the winning title of the 2024 CFA Society Toronto Ethics Challenge.

Key Points: 
  • On February 08, 2024, University of Waterloo - School of Accounting and Finance was awarded the winning title of the 2024 CFA Society Toronto Ethics Challenge.
  • This year’s competing teams were students from DeGroote School of Business - McMaster University, School of Accounting & Finance - University of Waterloo, Schulich School of Business - York University and University of Toronto, Scarborough.
  • The winning team, University of Waterloo - School of Accounting and Finance, will advance to the national level of the competition at the 2024 CFA Societies Canada Ethics Challenge on May 3, 2024.
  • The 2024 CFA Society Toronto Ethics Challenge is proudly sponsored by RBC Global Asset Management.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”